Tiziana Life Sciences = Submission of a Patent Application for Nasal Administration of Foralumab July 31, 2020 – Posted in: Tiziana Life Sciences (TILS)

31st July, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients New York/London, July 31, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has submitted a patent…